Entellus Medical, Inc. (ENTL) Downgraded by Zacks Investment Research
According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “
A number of other research firms also recently commented on ENTL. Deutsche Bank AG began coverage on shares of Entellus Medical in a report on Thursday, October 6th. They issued a buy rating and a $26.00 price objective for the company. Canaccord Genuity reiterated a buy rating and issued a $21.00 price objective on shares of Entellus Medical in a report on Friday, January 6th. BTIG Research reiterated a buy rating and issued a $25.00 price objective on shares of Entellus Medical in a report on Sunday, January 8th. Piper Jaffray Companies reissued a positive rating on shares of Entellus Medical in a research note on Wednesday, December 14th. Finally, Guggenheim began coverage on shares of Entellus Medical in a research note on Tuesday, December 6th. They issued a buy rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $23.60.
Entellus Medical (NASDAQ:ENTL) traded up 0.40% during mid-day trading on Tuesday, hitting $20.11. 53,139 shares of the stock traded hands. Entellus Medical has a 12 month low of $13.72 and a 12 month high of $22.63. The stock’s market cap is $379.36 million. The stock has a 50-day moving average price of $18.81 and a 200-day moving average price of $18.93.
Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings data on Thursday, November 3rd. The medical technology company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.13. The business earned $17.90 million during the quarter, compared to analyst estimates of $17.93 million. Entellus Medical had a negative net margin of 36.91% and a negative return on equity of 53.20%. The firm’s revenue was up 20.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.32) EPS. On average, equities analysts forecast that Entellus Medical will post ($1.44) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Entellus Medical, Inc. (ENTL) Downgraded by Zacks Investment Research” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright law. The correct version of this story can be accessed at http://www.watchlistnews.com/entellus-medical-inc-entl-downgraded-by-zacks-investment-research/1060329.html.
In related news, Director Brian E. Farley sold 20,158 shares of the stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $18.74, for a total transaction of $377,760.92. Following the completion of the transaction, the director now owns 454,581 shares of the company’s stock, valued at approximately $8,518,847.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Karen E. Peterson sold 10,160 shares of the stock in a transaction that occurred on Wednesday, January 4th. The stock was sold at an average price of $18.74, for a total transaction of $190,398.40. Following the transaction, the vice president now directly owns 43,384 shares of the company’s stock, valued at approximately $813,016.16. The disclosure for this sale can be found here. Corporate insiders own 9.10% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company bought a new position in Entellus Medical during the third quarter worth $143,000. Deimos Asset Management LLC bought a new position in Entellus Medical during the second quarter worth $183,000. Teachers Advisors Inc. boosted its position in Entellus Medical by 21.7% in the second quarter. Teachers Advisors Inc. now owns 10,533 shares of the medical technology company’s stock worth $192,000 after buying an additional 1,876 shares during the last quarter. California State Teachers Retirement System boosted its position in Entellus Medical by 36.0% in the second quarter. California State Teachers Retirement System now owns 15,717 shares of the medical technology company’s stock worth $287,000 after buying an additional 4,160 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Entellus Medical by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 17,025 shares of the medical technology company’s stock worth $312,000 after buying an additional 210 shares during the last quarter. 68.22% of the stock is owned by hedge funds and other institutional investors.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.